Thermo Fisher Scientific company profile
Company profile
Thermo Fisher Scientific has 125,000 employees and is headquartered in Waltham, United States.
Pharmaceutical and biotechnology companies, academic and government laboratories, clinical laboratories, environmental and industrial users, and hospitals make up the customer base of this group, which sells in markets around the world. Its offering spans reagents, instruments and consumables used in biological and medical research, tools for the discovery and production of drugs and vaccines, and diagnostics for infections and diseases. Analytical instruments, software and services serve pharmaceutical, academic and industrial users, while specialty diagnostics cover allergy, asthma and autoimmune disease testing, microbiology culture media, transplant typing and other clinical products. Laboratory products and pharma services with clinical research complete the range.
In the fiscal year ended December 2025, revenue reached 44.6 billion US dollars, up 3.9% from the previous year, and net income stood at 6.7 billion dollars. Non-US sales accounted for 50.1% of revenue, against 49.9% generated in the United States. The group employs 125,000 people and has its headquarters in Waltham, Massachusetts, where it was established in 1956.
Company facts
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Headquarters
- 168 Third Avenue, 02451, Waltham
- Employees
- 125,000
- Chief executive
- Marc Casper
- Founded
- 1956
- Fiscal year
- January - December
- Listing
- TMO · NYSE
- Indices
- S&P 500
- Currency
- USD
- ISIN
- US8835561023
- Website
- thermofisher.com
Thermo Fisher Scientific and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Thermo Fisher ScientificTMO | United States | $254.47B | 125,000 | 19.1% | 36.7 |
| DanaherDHR | United States | $161.75B | 58,000 | 22.0% | 38.1 |
| WatersWAT | United States | $90.45B | 15,000 | 16.0% | 192.6 |
| IDEXX LaboratoriesIDXX | United States | $55.2B | 11,000 | 32.5% | 46.8 |
| Agilent TechnologiesA | United States | $48.75B | 18,200 | 24.5% | 34.3 |
| IQVIA HoldingsIQV | United States | $42.63B | 95,000 | 13.9% | 31.5 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
